POLARAMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POLARAMINE (POLARAMINE).
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
| Metabolism | Hepatic metabolism via CYP450 enzymes; primary metabolite is deschloropheniramine. |
| Excretion | Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination |
| Half-life | Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment. |
| Protein binding | Approximately 85-90% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3-5 L/kg (wide distribution into tissues including CNS, consistent with anticholinergic and sedative effects). |
| Bioavailability | Oral: 70-80% (first-pass metabolism reduces absolute bioavailability; syrup may have slightly faster absorption). |
| Onset of Action | Oral: 30-60 minutes (tablet or syrup). Intravenous: 5-10 minutes. Topical ophthalmic: 15-30 minutes. |
| Duration of Action | Oral: 4-6 hours for antihistamine effect, but after multiple doses, up to 24 hours due to active metabolites. Clinical note: Sedative effect may persist longer. |
| Action Class | H1 Antihistaminics (First Generation) |
| Brand Substitutes | Synramine 2mg Tablet, Geodex 2mg Tablet, Dexamine 2mg Tablet, Alermine 2mg Tablet, Dexil 2mg Tablet, Diominic 6mg Tablet, Dexaller 6mg Tablet, Dexomak 6mg Tablet |
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use caution in severe renal impairment (CrCl <10 mL/min). |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh Class C). |
| Pediatric use | Children 2-6 years: 0.1 mg/kg orally every 6 hours; maximum 2 mg/dose. Children 6-12 years: 2 mg orally every 6 hours; maximum 6 mg/day. |
| Geriatric use | Initiate at 2 mg orally every 8 hours; titrate cautiously due to increased risk of dizziness, sedation, and anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POLARAMINE (POLARAMINE).
| Breastfeeding | Dexchlorpheniramine is excreted into breast milk in small amounts (M/P ratio not specifically reported). Common antihistamines are considered compatible with breastfeeding per AAP; however, high doses may cause drowsiness or irritability in infants. Use lowest effective dose for shortest duration. |
| Teratogenic Risk | Polaramine (dexchlorpheniramine) is an antihistamine; animal studies insufficient, human data limited. First trimester: potential minor malformations (cleft palate) from antihistamines overall but not established. Second/third trimester: no known fetal toxicity, but avoid near term due to possible association with retinopathy of prematurity and withdrawal symptoms (irritability, tremors) in neonates after third-trimester use. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to chlorpheniramine or any component","Neonates or premature infants","Breastfeeding (relative: use with caution if necessary)","Concomitant use with MAO inhibitors"]
| Precautions | ["Use with caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, bladder neck obstruction, or COPD.","May cause drowsiness; avoid driving or operating machinery.","Use in elderly may cause dizziness, sedation, and hypotension.","Use in children may cause paradoxical hyperexcitability."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. In third trimester, observe neonate for signs of anticholinergic effects (tachycardia, constipation, urinary retention) and transient withdrawal symptoms. |
| Fertility Effects | No well-documented effects on human fertility. Animal studies: no adverse effects on reproduction at clinically relevant doses. |